Yahoo Finance

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report. The analyst left the earnings call “particularly encouraged” by the oral VK2735 delivering on “injectables’-like” weight loss data, which Riley believes would be unprecedented in the space.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on VKTX:

• Viking Therapeutics price target lowered to $70 from $120 at Maxim

• Viking Therapeutics initiated with a Neutral at Citi

• Viking Therapeutics Reports Strong Trials and Financial Health

• Viking Therapeutics price target raised to $125 from $122 at Raymond James

• Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress